12:00 AM
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Clazosentan: Phase III expanded

Actelion said it expanded enrollment in the double-blind, placebo-controlled, international CONSCIOUS-2 trial to 1,146 from 765 patients in order to maintain the study's statistical power after a blinded review showed a lower than...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >